$-0.56 EPS Expected for Xencor, Inc. (XNCR)

October 13, 2018 - By Peter Kolinski

Investors sentiment increased to 1.82 in Q2 2018. Its up 0.12, from 1.7 in 2018Q1. It is positive, as 13 investors sold Xencor, Inc. shares while 26 reduced holdings. 26 funds opened positions while 45 raised stakes. 46.21 million shares or 5.48% more from 43.81 million shares in 2018Q1 were reported.
State Common Retirement Fund has 55,570 shares for 0% of their portfolio. Loomis Sayles And Communication Lp holds 371,469 shares or 0.03% of its portfolio. Moreover, D E Shaw And has 0% invested in Xencor, Inc. (NASDAQ:XNCR). 4.01 million are held by Blackrock. Numerixs Investment Inc accumulated 0.01% or 1,600 shares. Equitec Specialists Limited Liability Co holds 0.02% or 5,489 shares. Perceptive stated it has 1.07M shares or 1.04% of all its holdings. Great West Life Assurance Can holds 0% or 6,526 shares in its portfolio. Piermont Mgmt stated it has 7,170 shares. Maryland-based Proshare Advsr Limited Liability Com has invested 0.01% in Xencor, Inc. (NASDAQ:XNCR). Deutsche Retail Bank Ag holds 82,105 shares or 0% of its portfolio. Commercial Bank Of Mellon holds 0% or 244,232 shares in its portfolio. First Light Asset Management invested in 561,807 shares or 3.24% of the stock. Vanguard Grp Incorporated reported 0% stake. Macquarie Gp Limited has invested 0.01% of its portfolio in Xencor, Inc. (NASDAQ:XNCR).

Since June 13, 2018, it had 0 insider purchases, and 9 selling transactions for $24.07 million activity. STAFFORD JOHN S III sold $48,054 worth of stock. Foster Paul A also sold $1.84M worth of Xencor, Inc. (NASDAQ:XNCR) shares. 50,000 shares were sold by Dahiyat Bassil I, worth $2.03 million. Kuch John J sold 25,000 shares worth $1.04 million.

Analysts expect Xencor, Inc. (NASDAQ:XNCR) to report $-0.56 EPS on November, 6.They anticipate $0.23 EPS change or 69.70 % from last quarter’s $-0.33 EPS. After having $-0.46 EPS previously, Xencor, Inc.’s analysts see 21.74 % EPS growth. The stock increased 3.06% or $1.04 during the last trading session, reaching $35.04. About 254,658 shares traded. Xencor, Inc. (NASDAQ:XNCR) has risen 101.72% since October 14, 2017 and is uptrending. It has outperformed by 86.10% the S&P500.

Xencor, Inc. (NASDAQ:XNCR) Ratings Coverage

Among 4 analysts covering Xencor Inc (NASDAQ:XNCR), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Xencor Inc had 5 analyst reports since April 26, 2018 according to SRatingsIntel. The stock of Xencor, Inc. (NASDAQ:XNCR) earned “Buy” rating by Cantor Fitzgerald on Tuesday, May 8. The rating was maintained by Canaccord Genuity with “Buy” on Wednesday, May 9. On Monday, September 10 the stock rating was reinitiated by BTIG Research with “Buy”. Piper Jaffray maintained it with “Buy” rating and $4600 target in Thursday, April 26 report.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company has market cap of $1.96 billion. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. It currently has negative earnings. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies.

More news for Xencor, Inc. (NASDAQ:XNCR) were recently published by: Seekingalpha.com, which released: “Key events next week – healthcare” on October 12, 2018. Seekingalpha.com‘s article titled: “Xencor announces mid-stage Lupus data on XmAb 5871; shares down 7% premarket” and published on October 05, 2018 is yet another important article.

Xencor, Inc. (NASDAQ:XNCR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News